SCHEMBL30765674

SCHEMBL30765674

COC(=O)Cn1c(-c2ccccc2)ncc(-c2nc3c(s2)CCCC3)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 3/20 0.42
GLA P06280 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALOX15 P16050 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
F2RL3 Q96RI0 1/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765762 0.89 ALDH1A1 (0.42) ALDH1A1LMNAGLATSHRMAPK1
SCHEMBL30765989 0.80 KDM4E (0.51) ALDH1A1LMNAGLATSHRSMN1; SMN2
SCHEMBL30765599 0.72 CTRC (0.54) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL30765438 0.72 KDM4E (0.50) ALDH1A1LMNAGLATSHRSMN1; SMN2
SCHEMBL30765727 0.69 KDM4E (0.44) ALDH1A1LMNAGLATSHRSMN1; SMN2
SCHEMBL31558529 0.68 F10 (0.34) ALDH1A1LMNAGLATSHRMAPK1
SCHEMBL30765677 0.66 KDM4E (0.49) ALDH1A1GLAALOX15KDM4ECYP1A2
SCHEMBL17332419 0.66 NPC1 (0.51) ALDH1A1LMNAGLANPSR1SMN1; SMN2
SCHEMBL31750637 0.64 CYP1A2 (0.54) ALDH1A1LMNAGLATSHRSMN1; SMN2
SCHEMBL30765794 0.64 HDAC1 (0.46) ALDH1A1GLASMN1; SMN2KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed